The molecular motor dynein and its associated regulatory subunit dynactin have been implicated in several neurodegenerative conditions of the basal ganglia, such as Huntington's disease and Perry syndrome, an atypical Parkinson-like disease. This pathogenic role has been largely postulated from the existence of mutations in the dynactin subunit p150
Introduction
Axonal transport is a bidirectional process through which materials and signals are exchanged between the neuronal cell body and the synapse. Retrograde axonal transport is mediated by the cytoplasmic molecular motor dynein which functions in association with a multiprotein regulatory complex called dynactin (1) . Loss of dynein/dynactin function is thought to be an important factor in the pathogenesis of neurodegenerative diseases (2, 3) .
Indeed, impairment of retrograde axonal transport appears to be one of the earliest pathogenic events during neurodegeneration (1) , and transgenic inhibition of retrograde axonal transport in motor neurons is sufficient to drive the degeneration of these neurons (4, 5) . The involvement of dynactin in neurodegenerative diseases is supported by the discovery of mutations in the dynactin subunit p150 glued in familiar forms of motor neuron disease, including amyotrophic lateral sclerosis (ALS) and distal spinal and bulbar muscular atrophy (6) (7) (8) , as well as in Perry syndrome, a rare atypical form of Parkinson's disease resistant to L-DOPA (9, 10) . In vitro, the G59S mutation in p150 Glued leads to abnormal cytoskeletal dynamics accompanied by toxic protein aggregation (11) . In vivo, moderate neuron-specific overexpression of mutant dynactin causes motor neuron disease in mice (12) (13) (14) .
The mechanisms underlying the toxicity of mutant p150 Glued are still elusive because 4 neurodegeneration through impairment of dynein function. Several lines of evidence suggest that dynein itself is a modifier of the degeneration of striatal neurons in Huntington's disease (HD), a neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin gene. First, dynein, as well as p150 Glued , are binding partners of huntingtin and of huntingtin associated protein 1 (HAP1) (19, 20) . Second, the activity of the dynein motor is positively regulated by wild type huntingtin, and strongly decreased by the HD-associated expansion in the polyglutamine repeat domain of huntingtin (21, 22) . However, the effects of pathogenic huntingtin on axonal transport are widespread by affecting both anterograde and retrograde fast axonal transport (23) . Thus, direct genetic evidence linking retrograde axonal transport, in particular dynein, and striatal degeneration is still lacking.
The aim of this study was to provide such evidence. For this, we took advantage of the existence of mouse strains bearing point mutations in the dynein heavy chain gene (DYNC1H1) (24) . The legs at odd angles (loa) mutation represents a F580Y mutation, while the Cramping (Cra) mutation converts tyrosine 1055 to a cysteine (Y1055C). Both mutations are located in the domain involved in homodimerization of the molecular motor. Both of these mutations impair the ability of dynein motors to sustain fast retrograde transport in situations of cellular stress and lead to decreased retrograde transport in adult dynein mutant motor neurons (24, 25) . The phenotype of dynein mutant mice has been characterized in the peripheral nervous system, with the occurrence of a proprioceptive sensory neuropathy (26) (27) (28) but there are currently no study focusing on the central nervous system of these animals.
An initial report suggested that dynein mutant mice displayed lower motor neuron degeneration, but we and others failed to reproduce these findings (26) (27) (28) . In particular, we performed a longitudinal analysis of the neuromuscular phenotype of Cra/+ mice up to 24 months of age and found no evidence of motor neuron degeneration in these animals (27) .
Here, we show that the Cramping dynein mutation in mice leads to distinctive signs of striatal dysfunction. Furthermore, dynein mutant striatal neurons showed profound abnormalities in neurite outgrowth in vitro. These findings strongly support a pathophysiological function for dynein in degenerative diseases of basal ganglia including HD and Perry syndrome.
Results
The motor phenotype of Cra/+ mice is characterized by early muscle weakness,
progressive incoordination and hyperactivity
We first performed a battery of motor and behavioural tests in mice bearing the Cramping mutation in the dynein heavy chain gene (Cra/+). In our laboratory, Cra/+ mice showed reduced total and forelimb muscle grip strength as early as 3 months of age (figure 1A), and suffered from an impairment in motor coordination that mildly increased with aging, as observed using an accelerating rotarod test (figure 1B). Cra/+ mice displayed increased open field exploratory behaviour as revealed by increased track length and average velocity ( figure   1C ). No differences were observed in the number of rearings, indicating normal vertical behaviour (not shown). The level of anxiety appeared similar between Cra/+ mice and their wild-type littermates as assessed using the elevated plus maze paradigm ( figure 1D ). In the Morris water maze test, Cra/+ mice tended to spend more time in reaching the platform at 12, but not 3, months of age, as compared to wild-type animals. This was likely due to impaired motor incoordination rather than to spatial memory deficits since the observed difference between genotypes was annulled when considering the distance swum by the mice ( figure   1E ). Taken together, Cra/+ mice display muscle weakness and incoordination with increased open field activity in the absence of obvious spatial working memory deficits. 7 molecular weight of 32 kDa) positive medium spiny neurons (MSNs), the neuronal population comprising more than 95% of striatal neurons, using stereological analysis. The analysis of DARPP32 positive MSNs showed a non-significant trend towards decreased number at 6 months of age (figure 4). These data show that the phenotype of dynein mutant mice is rather due to neuronal dysfunction than to neurodegeneration in the striatum.
Altered dopamine signalling and D1 receptor binding in the striatum of Cra/+ mice Our histological observations in the striatum argue in favour of neuronal dysfunction that could eventually lead to motor disturbances. To test this hypothesis, we analysed the expression of a series of genes directly involved in striatal function. D1, but not D2, dopamine receptor mRNA levels were decreased in 8 months old Cra/+ mice as shown using RT-qPCR (figure 5A). D1 receptor expressing cells synthesize substance P, whereas D2
receptor expressing cells synthesize pre-proenkephalin. Thus, substance P, but not preproenkephalin, mRNA levels appeared decreased in 8 months old Cra/+ mice (figure 5A), which corroborates the selective down-regulation of the expression of D1 dopamine receptors in striatal neurons. It is therefore tempting to propose that Cra/+ mice suffer from D1 receptor striatal dysfunction that could underlie the motor disturbances observed in these animals. To directly determine whether this is the case, we performed positron emission tomography figure 2 ) and TH staining of dynein mutant striatum appeared normal (not shown), demonstrating that striatal atrophy is not a consequence of dopaminergic degeneration. Next we hypothesized that trophic factor deprivation of striatal neurons led to striatal atrophy. BDNF, the major trophic factor for this neuronal population, is produced in the cortex and anterogradely transported to the striatum. Cortical BDNF ablation leads to a roughly similar striatal atrophy and behavioural impairment than dynein mutation (34, 35) . At the mRNA level, BDNF expression was not decreased, but increased at 6 months of age in the cortex of Cra/+ mice (supplementary figure 3A) . BDNF levels appeared normal in the striatum of these mice using ELISA (supplementary figure 3B), suggesting that BDNF was appropriately produced and targeted to the striatum. Dynein mutation could also lead to a decreased cellular response of dynein mutant neurons to BDNF exposure. Indeed, exocytosis and endocytosis, which are dynein dependent events, appear indispensable for BDNF signal transduction (36, 37) . A major target of BDNF is increased DARPP32 transcription (38) and major transcriptional responses occur 3 to 4 hours after exposure to BDNF (39) . DARPP32
induction appeared similar between +/+, Cra/+ and Cra/Cra primary striatal neurons treated with BDNF during 4 hours (supplementary figure 3C) suggesting that the dynein mutation did not massively impair BDNF response of these neurons. In all, neither dopamine nor BDNF deprivation appeared to be a primary cause of dynein mutant striatal phenotype.
Cell autonomous defect in dynein mutant striatal neurons
To determine whether dynein mutant striatal neurons were intrinsically abnormal, we first 
Discussion
This study provides evidence for the in vivo requirement of dynein in the function of the striatum and indicates that this occurs through involvement of cytoplasmic dynein in neuritic arborisation. The consequences of these findings are important for neurodegenerative diseases affecting the basal ganglia.
Cra/+ mice suffer from motor and behavioural disturbances through their whole lifespan. Others and we have previously shown the occurrence of an early and relatively mild proprioceptive neuropathy in Cra/+ mice (26) (27) (28) , but this limited phenotype does not explain the overall behavioural and locomotor abnormalities observed here. First, muscle weakness is usually observed in patients presenting motor neuropathy, but not in patients affected by a pure sensory neuropathy (40) as in Cra/+ mice. Second, behavioural abnormalities, including limb clasping and hyperactivity, rather suggest a central involvement and do not comply with a pure sensory neuropathy. These behavioural abnormalities are suggestive of striatal involvement. Indeed, the early phase of the pathology in mouse models of HD is characterized by an increase in spontaneous motor activity (29) (30) (31) 41) . Similarly, transgenic mice lacking cortical BDNF or conditionally ablated for BDNF at adulthood display hindlimb and forelimb clasping (34, 35) , and mice deficient in PGC-1alpha, a transcriptional coactivator involved in the regulation of energy metabolism, also present with limb clasping and hyperactivity (42) . Importantly, all these transgenic animals display a clear-cut lesion in the striatum. This is particularly interesting, because the genetic ablation of D1 dopamine receptor expressing cells (that is, within the striatum) yields a motor phenotype very similar to that observed in mutant dynein mice (32) . In all, the selective down-regulation of the expression of D1 dopamine receptors, together with striatal atrophy, enlargement of lateral ventricles, decreased binding to either D1 or D2 dopamine receptors and the prominent astrocytosis that we found in the striatum of Cra/+ mice suggest that a striatal dysfunction can lead, at least in part, to the stereotyped motor disturbances in these mice. In summary, our findings provide direct evidence of the involvement of the axonal transport machinery, notably dynein, in the maintenance of striatal function and may have major implications for our understanding of basal ganglia diseases, such as HD and Perry syndrome.
Materials and methods

Animals
Heterozygous Cra/+ mice were obtained from Ingenium Pharmaceuticals AG, Martinsried, Germany. They were identified by tail DNA genotyping as previously described (24) .
Animals were maintained in a temperature-and humidity-controlled environment on a 12h
light /12h dark cycle, and received food and water ad libitum. For histological analysis, animals were deeply anesthetized with 1 mg/kg body weight ketamine chlorhydrate and 0.5 mg/kg body weight xylazine, and transcardially perfused with 4% paraformaldehyde in 0.1 M pH 7.4 phosphate buffer. Tissues were then quickly dissected, post-fixed for 24 hours in 4%
paraformaldehyde, and cryoprotected for 48 hours with 30% sucrose in PBS before cryostat sectioning. For biochemical analysis, animals were sacrificed and tissues were quickly dissected, snap frozen in liquid nitrogen and stored at -80°C until use. Animal manipulation followed current EU regulations and was performed under the supervision of authorized investigators.
Real time RT-PCR
Total RNA was extracted using Trizol (Invitrogen, Cergy-Pontoise, France) according to the manufacturer's instructions. cDNA synthesis was performed using 1 µg of total RNA (iScript cDNA Synthesis kit; Bio-Rad, Marne La Coquette, France). PCR analysis was carried out as described (27) on a Bio-Rad CFX96 System using iQSYBR Green Supermix. A specific standard curve was performed for each gene in parallel, and each sample was quantified in duplicate. PCR conditions were 3 min at 94°C, followed by 40 cycles of 45 s at 94°C and 10 s at 60°C. Data were analyzed using the iCycler software, and normalized to the reference genes encoding either the 18S ribosomal subunit and the RNA polymerase II mRNA. The primer pairs used are provided in supplementary table 1.
Testing of motor performance and behaviour
Muscle grip strength was measured using a Bioseb gripmeter (Vitrolles, France) on forelimbs and all limbs. Each assay was performed in triplicate and measurements were averaged. For behavioural analysis, C3H Cra/+ females were crossed with Bl6 males in order to compare with a group of mutant SOD1 (G93A) mice in mixed C3H/Bl6 background analyzed in parallel (60) . One week before the start of the tests, animals were brought to the behavioural analysis facility; single caged and handled every day. Only male mice were used for the tests. 
Analysis of brain astrocytosis
Brain sections comprising the anterior part of the caudate nucleus and the putamen were cut on a vibratome at a thickness of 50 µm (Leica Microsystems, Wetzlar, Germany) and were stained by indirect immunofluorescence, using an antibody directed against the specific astrocyte marker glial fibrillary acidic protein (GFAP, Santa Cruz Biotechnology, Heidelberg, Germany) following the manufacturer's instructions. Quantitative analysis of immunoreactivity was performed using ImageJ.
Stereological analysis of DARPP-32 and TH positive neurons
Coronal sections were cut in six series at a thickness of 35 µm throughout the brains using a freezing microtome. One series of free-floating brain sections were processed for immunohistochemistry either with a primary rabbit antibody against DARPP-32 ( 
Striatal neuron culture
Primary striatal neurons were cultured from E15 embryos issued from a cross between two heterozygous Cra/+ mice. Neurons from each embryo were cultured separately and genotype was determined post hoc by DNA genotyping of remaining embryos tissues. After enzymatic and mechanical dissociation, primary striatal neurons were plated at a density of 2.10 5 cells/ml on 0.1 mg/ml polyornithine pre-coated culture dishes and grown at 37°C in a humidified atmosphere (5% CO 2 /95% air). Culture media was composed of Neurobasal defined medium supplemented with B27, glutamax (2mM), KCl (25 mM) and gentamycin (50 µg/ml). Primary neurons were cultured for 7 days, and the culture media was changed every 2 days. BDNF treatment (Tocris Bioscience, Ellisville, USA) was performed the seventh day at the indicated concentration for 4 hours. 
BDNF ELISA
BDNF ELISA (Promega, Charbonnières-les-Bains, France) was performed as described by the provider.
Statistical analysis
Data are expressed as the mean ± SEM. Statistical analysis was accomplished using nonparametric Student t-test or ANOVA followed by Newman-Keuls multiple comparisons test (PRISM version 4.0b; GraphPad, San Diego, CA). Differences at P < 0.05 were considered significant. 
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